GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31/03/2026
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision [...]
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
31/03/2026
Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated [...]
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026
Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi- [...]
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
31/03/2026
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth Initial patient dosed in the First-in-Human clinical trial of ADCX-020, marking Adcytherix’s [...]
Proxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond Degradation
31/03/2026
Vienna, Austria, March 31, 2026 (GLOBE NEWSWIRE) -- Vienna, Austria, March 31, 2026 - Proxygen, a biotechnology company pioneering the discovery of molecular glue degraders and next-generation proximity-based [...]
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31/03/2026
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant [...]
electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
31/03/2026
ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join [...]
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
31/03/2026
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show [...]
Stryker names Nick Mead Vice President, Investor Relations
31/03/2026
Jason Beach appointed Vice President, Group CFO, MedSurg and Neurotechnology Portage, Michigan, March 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today Nick Mead [...]
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
31/03/2026
NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
Anathapindika Shines Spotlight on Detoxification During National Nutrition Month
31/03/2026
The Brand Brings Its Signature Focus on Removing, Not Just Adding, to the Nutrition Conversation in March Fort Lauderdale, FL, March 31, 2026 (GLOBE NEWSWIRE) -- March is National Nutrition Month. As part of the ongoing [...]
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
31/03/2026
Decision Expands Coverage to National Preferred Formulary Commercially Insured Lives MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical [...]
MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation
31/03/2026
ST. LOUIS, March 31, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc. , a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced receipt of [...]
Pheast Therapeutics Advances PHST001, an IgG4 Anti-CD24 Monoclonal Antibody, into Phase 1b Combination Cohorts
31/03/2026
First patient dosed in Phase 1b portion of ongoing Phase 1 study evaluating PHST001 in combination with chemotherapy Company to present three abstracts at AACR 2026, including preliminary clinical data and two [...]
Annovis Publishes Historical Review of Buntanetap in The Scientist
31/03/2026
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
31/03/2026
Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the first oral antiviral candidate being developed for norovirus treatment and prevention No approved treatments or [...]
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
31/03/2026
Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®
31/03/2026
Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated [...]
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
31/03/2026
Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum